Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation

被引:35
作者
Hebart, H
Schroder, A
Loffler, J
Klingebiel, T
Martin, H
Wassmann, B
Gerneth, F
Rabenau, H
Jahn, G
Kanz, L
Muller, CA
Einsele, H
机构
[1] UNIV TUBINGEN,MED KLIN,ABT 2,KINDERKLIN,INST MED INFORMAT VERARBEITUNG,D-7400 TUBINGEN,GERMANY
[2] UNIV TUBINGEN,ABT MED VIROL,TUBINGEN,GERMANY
[3] UNIV FRANKFURT,ZENTRUM INNERE MED,D-6000 FRANKFURT,GERMANY
[4] UNIV FRANKFURT,INST MED VIROL,D-6000 FRANKFURT,GERMANY
关键词
D O I
10.1086/516484
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Sensitive screening for cytomegalovirus (CMV) by polymerase chain reaction (PCR) following autologous bone marrow or peripheral blood progenitor cell transplantation has not been evaluated, In a three-center study, 98 autograft transplant recipients were prospectively screened for CMV infection by PCR and culture techniques. At a median of 20 days (range, 3-28) after transplantation, 21 (39.6%) of 53 CMV-seronegative patients were PCR positive for CMV, and at a median of 17 days (range, 7-84) after transplantation, 19 (42.2%) of 45 CMV-seropositive patients were PCR positive for CMV. Low-level DNAemia (1-10 fg CMV DNA/mL blood) occurred for 1 week in 31 patients but was never associated with CMV disease. Of 9 patients who presented with at least two consecutive positive PCR results, 1 developed CMV pneumonia, No patients died because of CMV disease. Screening for CMV infection by PCR had a negative predictive value of 100% (as also observed after allogeneic transplantation), but its positive predictive value was significantly lower.
引用
收藏
页码:1490 / 1493
页数:4
相关论文
共 15 条
[1]   COMPARISON OF PLASMA PCR AND BRONCHOALVEOLAR LAVAGE FLUID CULTURE FOR DETECTION OF CYTOMEGALOVIRUS-INFECTION IN ADULT BONE-MARROW TRANSPLANT RECIPIENTS [J].
ASPIN, MM ;
GALLEZHAWKINS, GM ;
GIUGNI, TD ;
TEGTMEIER, B ;
LANG, DJ ;
SCHMIDT, GM ;
FORMAN, SJ ;
ZAIA, JA .
JOURNAL OF CLINICAL MICROBIOLOGY, 1994, 32 (09) :2266-2269
[2]  
BOECKH M, 1992, BLOOD, V80, P1358
[3]   FAILURE OF HIGH-DOSE ACYCLOVIR TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER AUTOLOGOUS MARROW TRANSPLANTATION [J].
BOECKH, M ;
GOOLEY, TA ;
REUSSER, P ;
BUCKNER, CD ;
BOWDEN, RA .
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (04) :939-943
[4]  
BOECKH M, 1995, 35 INT C ANT AG CHEM
[5]   POLYMERASE CHAIN-REACTION TO EVALUATE ANTIVIRAL THERAPY FOR CYTOMEGALOVIRUS DISEASE [J].
EINSELE, H ;
EHNINGER, G ;
STEIDLE, M ;
VALLBRACHT, A ;
MULLER, M ;
SCHMIDT, H ;
SAAL, JG ;
WALLER, HD ;
MULLER, CA .
LANCET, 1991, 338 (8776) :1170-1172
[6]  
EINSELE H, 1995, BLOOD, V86, P2815
[7]   GANCICLOVIR PROPHYLAXIS TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC MARROW TRANSPLANT [J].
GOODRICH, JM ;
BOWDEN, RA ;
FISHER, L ;
KELLER, C ;
SCHOCH, G ;
MEYERS, JD .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (03) :173-178
[8]   A three-center European external quality control study of PCR for detection of cytomegalovirus DNA in blood [J].
Grundy, JE ;
Ehrnst, A ;
Einsele, H ;
Emery, VC ;
Hebart, H ;
Prentice, HG ;
Ljungman, P .
JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (05) :1166-1170
[9]  
Hebart H, 1996, BONE MARROW TRANSPL, V17, P861
[10]  
IMBERTMARCILLE BM, 1995, SCAND J INFECT DIS S, V99, P15